Clinical research

Comparison of mismatch negativity in patients with schizophrenia and depression

  • Meng-ting SHEN ,
  • Xuan-hong ZHANG ,
  • Zhen-ying QIAN ,
  • Hui LI ,
  • Jian-hua SHENG ,
  • Ji-jun WANG ,
  • Ying-ying TANG
Expand
  • Department of EEG and Neuroimaging, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
ZHANG Xuan-hong, E-mail: zhangxuanhong403@163.com. #Co-corresponding authors.
TANG Ying-ying, E-mail: yytang0522@gmail.com

Online published: 2021-08-13

Supported by

National Natural Science Foundation of China(81671332);National Natural Science Foundation of Shanghai(7ZR1424700)

Abstract

Objective

·To compare the difference of mismatch negativity (MMN) between first-episode schizophrenia and depression and its correlation with clinical characteristics, and explore the role of pre-attention processing in the mechanisms of schizophrenia and depression.

Methods

·Twenty patients with schizophrenia and 19 patients with depression were selected in the outpatient department of Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine from January 2014 to December 2016. Healthy controls were also recruited. The Positive and Negative Syndrome Scale (PANSS) was used to measure the clinical symptoms of schizophrenia. Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were used to measure the clinical symptoms of depression. All patients and healthy controls completed MMN detection and clinical scale assessments. The amplitudes and latencies of duration MMN (DMMN) and frequency MMN (FMMN) were analyzed by repeated measures analysis of variance with group as the between-group factors. The midline electrodes (Fz, Fcz) were used as the with-in group factor; meanwhile, region (F, Fc) and laterality (1 for left, 2 for right) were used as the within-group factors for lateral electrodes and the factor sex was used as covariate. Partial correlations was performed to find the correlation between MMN and clinical characteristics.

Results

·① The amplitude of DMMN in patients with schizophrenia 2 for [(-2.70±2.46) μV)] was lower than that in patients with depression [(-5.06±0.46) μV] and healthy controls [(-5.15±0.43) μV] (both P≤0.001). No significant group differences of DMMN latency were observed at midline or lateral electrodes (All P>0.05). ② There was no significant group difference of FMMN amplitudes at midline electrodes (P>0.05) but a significant between-group difference at lateral electrodes (P=0.040). No significant group differences of FMMN latency were observed at midline or lateral electrodes (All P>0.05). ③ There was a significant correlation between DMMN amplitudes at F2 (P=0.042) or Fz (P=0.032) and general scores of PANSS in schizophrenia patients. There was no correlation in depression patients.

Conclusion

·Abnormality of DMMN exists in the patients with first episode schizophrenia but not in the patients with depression, suggesting that DMMN amplitudes may work as a biological marker to distinguish schizophrenia and depression.

Cite this article

Meng-ting SHEN , Xuan-hong ZHANG , Zhen-ying QIAN , Hui LI , Jian-hua SHENG , Ji-jun WANG , Ying-ying TANG . Comparison of mismatch negativity in patients with schizophrenia and depression[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(8) : 1041 -1045 . DOI: 10.3969/j.issn.1674-8115.2021.08.007

References

1 Javitt DC, Spencer KM, Thaker GK, et al. Neurophysiological biomarkers for drug development in schizophrenia[J]. Nat Rev Drug Discov, 2008, 7(1): 68-83.
2 Michie PT, Malmierca MS, Harms L, et al. Understanding the neurobiology of MMN and its reduction in schizophrenia[J]. Biol Psychol, 2016, 116: 1-3.
3 Adell A. Brain NMDA receptors in schizophrenia and depression[J]. Biomolecules, 2020, 10(6): 947.
4 Wu JQ, Green MJ, Gardiner EJ, et al. Altered neural signaling and immune pathways in peripheral blood mononuclear cells of schizophrenia patients with cognitive impairment: a transcriptome analysis[J]. Brain Behav Immun, 2016, 53: 194-206.
5 Harada E, Satoi Y, Kikuchi T, et al. Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression[J]. Neuropsychiatr Dis Treat, 2016, 12: 1599-1607.
6 Donaldson KR, Novak KD, Dan FT, et al. Associations of mismatch negativity with psychotic symptoms and functioning transdiagnostically across psychotic disorders[J]. J Abnorm Psychol, 2020, 129(6): 570-580.
7 Koshiyama D, Kirihara K, Tada M, et al. Reduced auditory mismatch negativity reflects impaired deviance detection in schizophrenia[J]. Schizophr Bull, 2020, 46(4): 937-946.
8 Atkinson RJ, Michie PT, Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis[J]. Biol Psychiatry, 2012, 71(2): 98-104.
9 Chen J, Zhang Y, Wei DH, et al. Neurophysiological handover from MMN to P3a in first-episode and recurrent major depression[J]. J Affect Disord, 2015, 174: 173-179.
10 Toyomaki A, Kusumi I, Matsuyama T, et al. Tone duration mismatch negativity deficits predict impairment of executive function in schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32(1): 95-99.
11 Magno E, Yeap S, Thakore JH, et al. Are auditory-evoked frequency and duration mismatch negativity deficits endophenotypic for schizophrenia? High-density electrical mapping in clinically unaffected first-degree relatives and first-episode and chronic schizophrenia[J]. Biol Psychiatry, 2008, 64(5): 385-391.
12 Bonetti L, Haumann NT, Vuust P, et al. Risk of depression enhances auditory Pitch discrimination in the brain as indexed by the mismatch negativity[J]. Clin Neurophysiol, 2017, 128(10): 1923-1936.
13 Anaya C, Torrent C, Caballero FF, et al. Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life[J]. Acta Psychiatr Scand, 2016, 133(5): 386-398.
14 Nagai T, Kirihara K, Tada M, et al. Reduced mismatch negativity is associated with increased plasma level of glutamate in first-episode psychosis[J]. Sci Rep, 2017, 7(1): 2258.
15 顾君, 徐清, 刘晓伟, 等. 抑郁症与单纯型精神分裂症鉴别诊断中定量脑电图的应用价值研究[J]. 中国全科医学, 2014, 17(20): 2312-2316.
16 Koshiyama D, Kirihara K, Tada M, et al. Association between mismatch negativity and global functioning is specific to duration deviance in early stages of psychosis[J]. Schizophr Res, 2018, 195: 378-384.
17 Koshiyama D, Kirihara K, Tada M, et al. Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis[J]. Schizophr Res, 2017, 190: 32-38.
18 Murphy TK, Haigh SM, Coffman BA, et al. Mismatch negativity and impaired social functioning in long-term and in first episode schizophrenia spectrum psychosis[J]. Front Psychiatry, 2020, 11: 544.
19 Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients[J]. Mol Psychiatry, 2006, 11(2): 118-119.
20 Qiao ZX, Yu YM, Wang L, et al. Impaired pre-attentive change detection in major depressive disorder patients revealed by auditory mismatch negativity[J]. Psychiatry Res, 2013, 211(1): 78-84.
21 Kaut O, Schmitt I, Hofmann A, et al. Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression[J]. Eur Arch Psychiatry Clin Neurosci, 2015, 265(4): 331-341.
22 Jaso BA, Niciu MJ, Iadarola ND, et al. Therapeutic modulation of glutamate receptors in major depressive disorder[J]. Curr Neuropharmacol, 2017, 15(1): 57-70.
23 Raith H, Schuelert N, Duveau V, et al. Differential effects of traxoprodil and S-ketamine on quantitative EEG and auditory event-related potentials as translational biomarkers in preclinical trials in rats and mice[J]. Neuropharmacology, 2020, 171: 108072.
24 Salisbury DF, Shafer AR, Murphy TK, et al. Pitch and duration mismatch negativity and heschl's gyrus volume in first-episode schizophrenia-spectrum individuals[J]. Clin EEG Neurosci, 2020, 51(6): 359-364.
25 Mu Z, Chang Y, Xu J, et al. Pre-attentive dysfunction of musical processing in major depressive disorder: a mismatch negativity study[J]. J Affect Disord, 2016, 194: 50-56.
26 He W, Chai H, Zheng LL, et al. Mismatch negativity in treatment-resistant depression and borderline personality disorder[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2010, 34(2): 366-371.
27 Bissonnette JN, Francis AM, Hull KM, et al. MMN-indexed auditory change detection in major depressive disorder[J]. Clin EEG Neurosci, 2020, 51(6): 365-372.
Outlines

/